Prion-related diseases pose a potential threat to our blood supply. Currently, there are no diagnostic tests for prion-related diseases, which are invariably fatal. This technology is designed to use specific ligands to remove pathogens from transfusion blood products by a biocompatible filtration process. Our aptamers, which are RNA molecules, are specific for prion proteins. Additional financial terms of the agreement were not disclosed.
Prions are conformational misfoldings of a normal protein.
The Company maintains development and commercialization partnerships with Pall Corporation, Amersham Pharmacia Biotech, and Haemonetics Corporation. About Oxford University Oxford University is a global centre of excellence for research in the humanities and sciences and currently has the highest international research standing of all UK universities. In the financial year 1999-2000, Oxford attracted over 130 million in external research income, from industry, charities and government organisations, and negotiated over 2,000 research contracts. The combined value of Oxford's companies has reached 2 billion, using quoted market capitalisations and investor valuations for unquoted companies and these companies have created 4,000 jobs and some 30 millionaires . Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.